The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy.
C. Denkert
Stock Ownership - Sividon Diagnostics
R. Kronenwett
Employment or Leadership Position - Sividon Diagnostics
Stock Ownership - Sividon Diagnostics
S. Loibl
No relevant relationships to disclose
V. Nekljudova
No relevant relationships to disclose
S. Darb-Esfahani
No relevant relationships to disclose
B. Gerber
No relevant relationships to disclose
B. Sinn
No relevant relationships to disclose
C. Petry
Employment or Leadership Position - Sividon Diagnostics
Stock Ownership - Sividon Diagnostics
I. Bauerfeind
No relevant relationships to disclose
J. Budczies
No relevant relationships to disclose
M. Rezai
No relevant relationships to disclose
M. Dietel
Stock Ownership - Sividon Diagnostics
I. Schrader
No relevant relationships to disclose
G. Kunz
No relevant relationships to disclose
G. Von Minckwitz
No relevant relationships to disclose